SABCS 2025

Hope S. Rugo, MD, discusses the Phase III evERA Breast Cancer trial at SABCS 2025, revealing clinically meaningful improvements with giredestrant plus everolimus for ER-positive, HER2-negative metastatic breast cancer previously treated with a CDK4/6 inhibitor. Subgroup analyses show benefits regard

Thorsten Kühn MD PhD discusses findings from the AXSANA/EUBREAST 3(R) study at SABCS 2025. The research indicates that breast cancer patients who convert from clinically node-positive to node-negative after neoadjuvant chemotherapy do not require axillary lymph node dissection. Less invasive surgical staging procedures were found to be non-inferior in terms of three-year outcomes, irrespective of tumor type or initial stage.

This episode features an interview with Erika Hamilton MD at the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Hamilton discusses findings from the HER2CLIMB-05 trial, showing that adding tucatinib to trastuzumab and pertuzumab significantly improves progression-free survival in patients with HER2-positive metastatic breast cancer as first-line maintenance therapy, with no new safety signals. This small molecule HER2 inhibitor offers a promising new option.

At SABCS 2025, Gaorav Gupta MD PhD presented findings from the TBCRC-053 (P-RAD) study. The research showed that pre-operative radiation therapy significantly increased T-cell infiltration in hormone receptor-positive, HER2-negative invasive breast cancer. This novel approach could enhance anti-tumor immunity and boost responses to systemic therapies like immunotherapy and chemotherapy in this common breast cancer subtype.

Dr. Christian F. Singer discusses findings from the ABCSG 18 Study at the 2025 San Antonio Breast Cancer Symposium. The research indicates that post-menopausal women with ER-positive early breast cancer treated with denosumab and aromatase inhibitors show enhanced bone protection and improved long-term outcomes if their tumors are also positive for the progesterone receptor. This suggests PR-positive tumors drive the benefit of adjuvant denosumab.

Alexis Ann LeVee MD presented novel research at the 2025 San Antonio Breast Cancer Symposium. Her team's study, the randomized phase II neoHIP trial, revealed that pre-operative gut microbiome composition predicts pathologic complete response to immune checkpoint inhibition in patients with early-stage HER2-positive breast cancer. This highlights the microbiome's crucial role in influencing treatment outcomes for HER2-positive breast cancer.

Safna Naozer Virji MBBS FPBS was interviewed at the 2025 San Antonio Breast Cancer Symposium regarding her study on oncoplastic breast cancer surgery. Her research from Pakistan reported high efficacy and superior psychosocial outcomes for patients in low or middle-income settings. The study demonstrated low margin positivity, excellent long-term survival, and high patient-reported cosmetic satisfaction, supporting broader use of OBS in resource-limited areas.